#ES­MO20: Out to beat Tagris­so, J&J touts 100% ORR for EGFR bis­pe­cif­ic/TKI com­bo — fu­el­ing a quick leap to PhI­II

J&J’s one-two punch on EGFR-mu­tant non-small cell lung can­cer has turned up some promis­ing — al­though de­cid­ed­ly ear­ly — re­sults, fu­el­ing the idea that there’s yet room to one up on third-gen­er­a­tion ty­ro­sine ki­nase in­hibitors.

Twen­ty out of 20 ad­vanced NSCLC pa­tients had a re­sponse af­ter tak­ing a com­bi­na­tion of an in-house TKI dubbed laz­er­tinib and ami­van­tam­ab, a bis­pe­cif­ic an­ti­body tar­get­ing both EGFR and cMET en­gi­neered on part­ner Gen­mab’s plat­form, J&J re­port­ed at ES­MO. All were treat­ment-naïve, and none has seen their can­cer progress at a me­di­an fol­low-up of sev­en months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER